… transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the … perspective in guiding the Company in the translation of Axiomer, our leading RNA editing platform technology, to the …
… RNA therapies based on its proprietary ADAR-mediated Axiomer™ RNA editing technology platform, today announced … 30 days following the presentation date. About Axiomer ™ ProQR is pioneering a next-generation RNA base …
… Clinical Trial Application (CTA) advancing ProQR’s Axiomer™ ADAR-mediated RNA editing platform into clinical … a next-generation RNA base editing technology called Axiomer™, which could potentially yield a new class of …
… Cardiovascular Disease targeting B4GALT1 Development of Axiomer ® RNA base editing technology platform continues … with successful defense of opposition against a key Axiomer patent protecting ADAR-mediated RNA editing … against our strategy to accelerate the development of Axiomer,” said Daniel A. de Boer, Chief Executive Officer of …
… strategy to focus on accelerating the development of Axiomer ® RNA base-editing technology platform across … RNA editing technology – Accelerate development of the Axiomer ® RNA base-editing technology platform, including an … The Company will accelerate the development of its Axiomer ® RNA editing platform and pipeline activities and …
… transformative RNA therapies based on its proprietary Axiomer® RNA editing technology platform, today announced … webcast will be available for approximately 30 days. About Axiomer ® ProQR is pioneering a next-generation RNA base …